ArticleBMC public health2022
COVID-19 hot-spot strategy: a special innovation in pandemic response, Oyo State Nigeria.
Article in BMC public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Acceptability of COVID-19 self-testing among social and clinical vulnerable populations using a decentralized testing model in Abuja, Nigeria; A mixed methods analysis of an implementation study.PLOS global public health · 2026Article
- A cross-sectional survey of COVID-19 testing status among vaccine recipients in Gombe State, North-Eastern Nigeria.BMC public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCOVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a pandemic. Oyo state, Nigeria with a population of 9,233,010, recorded the first case of COVID-19 on the 12th of March 2020 and it is among the highest contributing States to the nation's burden of the disease with 3267 confirmed cases, including 40 deaths as of date, with an overall test positivity rate of 18.1%, far higher compared to the National average within a limited period from recorded index case. A 'Hotspot strategy' was designed by the Presidential Task Force on COVID-19 and Oyo State was selected to implement the strategy through upscaling case detection, isolation and treatment, quarantine of contacts and strengthening public health and social measures.
methodsWe used a descriptive cross-sectional survey of 3 identified hotspot Local Government Areas (LGAs) in Oyo State using mobile phones under Surveillance, Outbreak Response Management and Analysis System (SORMAS) platform to collect data from October to December 2020. Interventions comprised of enhanced active case search, contact line listing, contact investigation, and contact follow-up as well as to facilitate data collection and entry, community sensitization and management of alert/rumors. Baseline information and that after the 3-month period was then analyzed with the descriptive statistics presented.
resultsThe implementation of the hotspot strategy was shown to have had a major impact in Irepo LGA, where more than a 100% increase in samples tested, confirmed cases, contacts listed and contacts followed were recorded, while there were no significance changes noticed in Ibadan North and Lagelu LGAs. However, test positivity rates among contacts were found to be quite high in Ibadan North LGA (48%), compared to the other two, even though Lagelu LGA (5.7%) tested more contacts than Ibadan North.
conclusionThe observed increase in number of samples tested, cases confirmed, contact listed and investigated as well as test positivity rate in the 3 LGAs after the intervention implies that the hotspot strategy can be said to have contributed positively to the sensitivity of COVID-19 surveillance in Oyo State, Nigeria. This implies that strengthening this 'hotspot strategy' may be a key area of focus to improve COVID-19 surveillance sensitivity and response and in turn may help in breaking the transmission and bringing the pandemic to a halt.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.